Eurasian Journal of Biosciences


Introduction: The latest paradigm proposes that imbalance of Treg and Th17 cells play a significant role in Systemic Lupus Erythematosus (SLE) pathogenesis. The influence of IL-23 and IL-17 on the pathogenesis of SLE remains controversial. This study aimed to observe the role of IL-23/IL17 axis in the pathogenesis of SLE as disease activity using Systemic Lupus Activity Measure (SLAM) index.
Methods: This cross-sectional study analyzed thirty blood serum specimens taken from female patients with SLE diagnosed by the 1997 ACR criteria. All samples were analyzed for IL-23 and IL-17 serum level using ELISA method. Pearson’s/Spearman’s correlation test and Path analysis were used for statistical analysis.
Results: Thirty female subjects aged 31.3±10.46 years all manifested with hematology abnormalities and arthritis posed as the most common clinical manifestation. Both IL-23 and IL-17 levels increased at 625.33 pg/mL and 34.53 pg/mL, respectively. Disease activity resulted in a high mean SLAM score of 29.3±3.9. No correlation was found between serum IL-23 and serum IL-17 (r=0.089; p>0.05). Furthermore, IL-17 and IL-23 did not significantly correlate to disease activity (r=0.026; p>0.05); (r=0.116; p>0.05).
Conclusion: There was no significant correlation between IL-23 and IL-17 with SLE disease activity.


  • Adam FM, Nara MG, & Adam JM, (2006) Fasting insulin, adiponectin, hs-CRP levels, and the components of metabolic syndrome. Acta medica Indonesiana 38(4): 179–184.
  • Bertsias G, Cervera T, & Boumpas D, (2017) Systemic lupus erythematosus: pathogenesis and clinical features. 2012. URL: http://www. eular. org/myuploaddata/files/sample% 20chapter20_mod
  • Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, Yu CY, Hebert LA, & Rovin BH, (2010) The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 19(11): 1272–1280.
  • Chaichian Y, & Utset TO, (2013) Targeted therapies in systemic lupus erythematosus: a state-of-the-art review. J Clin Cell Immunol S 6: 2.
  • Cheng F, Guo Z, Xu H, Yan D, & Li Q, (2009) Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Annals of the rheumatic diseases 68(4): 604–606.
  • Crispín JC, Kyttaris VC, Terhorst C, & Tsokos GC, (2010) T cells as therapeutic targets in SLE. Nature Reviews Rheumatology 6(6): 317.
  • Du J, Li Z, Shi J, & Bi L, (2014) Associations between serum interleukin-23 levels and clinical characteristics in patients with systemic lupus erythematosus. Journal of international medical research 42(5): 1123–1130.
  • Galil SMA, Ezzeldin N, & El-Boshy ME, (2015) The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine 76(2): 280–287.
  • Ghanima ATA, Elolemy GG, Ganeb SS, Elazem AAA, & Abdelgawad ER, (2012) Role of T helper 17 cells in the pathogenesis of systemic lupus erythematosus. Egypt J Immunol 19: 25–33.
  • Handono K, Hasanah D, Kalim H, & Mawarti H, (2013) The association among serum levels of vitamin D, TGF-β/IL-6 balance and Treg/Th17 balance in systemic lupus erythematosus patients in Indonesia. International Journal of Biochemistry and Biotechnology 2(9): 490–496.
  • Jakes RW, Bae S, Louthrenoo W, Mok C, Navarra S V, & Kwon N, (2012) Systematic review of the epidemiology of systemic lupus erythematosus in the Asia‐Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis care & research 64(2): 159–168.
  • Leng R-X, Pan H-F, Chen G-M, Wang C, Qin W-Z, Chen L-L, Tao J-H, & Ye D-Q, (2010) IL-23: a promising therapeutic target for systemic lupus erythematosus. Archives of medical research 41(3): 221–225.
  • Mak TW, Saunders ME, and Je BD, (2014) Primer to the Immune Response. Second Edi $ on. AP Cell. Elsevier) London, UK
  • Marpaung B, Ginting AR, & Sjah OKM, (2018) Serum midkine levels in systemic lupus erythematosus. Open Access Macedonian Journal of Medical Sciences 6(8): 1323–1327.
  • Martin JC, Baeten DL, & Josien R, (2014) Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clinical immunology 154(1): 1–12.
  • Maule WJ, (2011) Pathogenesis & future treatments of systemic lupus erythematosus: the role of cytokines and anti-cytokines?: peer reviewed review. Medical Technology SA 25(1): 5–17.
  • McCarthy EM, Smith S, Lee RZ, Cunnane G, Doran MF, Donnelly S, Howard D, O’Connell P, Kearns G, & Ní Gabhann J, (2014) The association of cytokines with disease activity and damage scores in systemic lupus erythematosus patients. Rheumatology 53(9): 1586–1594.
  • Moftah RF, & Hassan E-S, (2016) AB0039 Interleukin-17 in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients: Correlation with Clinical Presentation, Laboratory Parameters and Activity Indices. BMJ Publishing Group Ltd
  • Mok MY, Wu HJ, Lo Y, & Lau CS, (2010) The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. The Journal of Rheumatology 37(10): 2046–2052.
  • Oke V, Brauner S, Larsson A, Gustafsson J, Zickert A, Gunnarsson I, & Svenungsson E, (2017) IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE). Arthritis research & therapy 19(1): 139.
  • Patrick J, Marpaung B, & Ginting Y, (2018) Differences of serum procalcitonin levels between bacterial infection and flare in systemic lupus erythematosus patients. In: L., W., D., W., W., M., J.K., B., P.C., E., M., de J., and U., Z. (eds.) Vol. 125. Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia: Institute of Physics Publishing
  • Puwipirom H, Hirankarn N, Sodsai P, Avihingsanon Y, Wongpiyabovorn J, & Palaga T, (2010) Increased interleukin-23 receptor+ T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Arthritis research & therapy 12(6): R215.
  • Sabry A, El-husseini A, Mahmoud K, Eldahshan KF, George SK, Abdel-Khalek E, El-Shafey EM, & Abo-Zenah H, (2006) Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 35(3–4): 148–153.
  • Samad R, Akbar FH, Willianto OA, Malinta QU, & Namirah HA, (2019) Effect of scaling and root planing treatment on levels Hs-CRP in Indonesian patients with risk of cardiovascular disease. Pesquisa Brasileira em Odontopediatria e Clinica Integrada 19(1):.
  • Shankar S, & Behera V, (2014) Advances in management of systemic lupus erythematosus. Journal of Mahatma Gandhi Institute of Medical Sciences 19(1): 28.
  • Sibarani H, & Zubir Z, (2018) Systemic lupus erythematosus in a male patient. In: L., W., D., W., W., M., J.K., B., P.C., E., M., de J., and U., Z. (eds.) Vol. 125. Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia: Institute of Physics Publishing
  • Stritesky GL, Yeh N, & Kaplan MH, (2008) IL-23 promotes maintenance but not commitment to the Th17 lineage. The Journal of Immunology 181(9): 5948–5955.
  • Tanasescu C, Balanescu E, Balanescu P, Olteanu R, Badea C, Grancea C, Vagu C, Bleotu C, Ardeleanu C, & Georgescu A, (2010) IL-17 in cutaneous lupus erythematosus. European journal of internal medicine 21(3): 202–207.
  • Vincent FB, Northcott M, Hoi A, Mackay F, & Morand EF, (2013) Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis research & therapy 15(4): R97.
  • Wang A, Guilpain P, Chong BF, Chouzenoux S, Guillevin L, Du Y, Zhou XJ, Lin F, Fairhurst A, & Boudreaux C, (2010) Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis & Rheumatism 62(11): 3436–3446.
  • Wong CK, Lit LCW, Tam LS, Li EKM, Wong PTY, & Lam CWK, (2008) Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clinical immunology 127(3): 385–393.
  • Wuryana D, Suryana BPP, & Yulistiani Y, (2016) Effectivity and renal safety of cyclosporine and methylprednisolone combination therapy in patients with systemic lupus erythematosus (SLE). Folia Medica Indonesiana 51(3): 156–161.
  • Xia LP, Li BF, Shen H, & Lu J, (2015) Interleukin-27 and interleukin-23 in patients with systemic lupus erythematosus: possible role in lupus nephritis. Scandinavian journal of rheumatology 44(3): 200–205.
  • Yanih I, (2016) Quality of Life in Patient with Systemic Lupus Erythematosus (SLE). Jurnal Berkala Epidemiologi 4(1): 1–12.
  • Yao Y, Wang JB, Xin MM, Li H, Liu B, Wang LL, Wang LQ, & Zhao L, (2016) Balance between inflammatory and regulatory cytokines in systemic lupus erythematosus. Genet Mol Res 15(2): 1–8.
  • Zhang Z, Kyttaris VC, & Tsokos GC, (2009) The role of IL-23/IL-17 axis in lupus nephritis. The Journal of Immunology 183(5): 3160–3169.
  • Zhao X-F, Pan H-F, Yuan H, Zhang W-H, Li X-P, Wang G-H, Wu G-C, Su H, Pan F-M, & Li W-X, (2010) Increased serum interleukin 17 in patients with systemic lupus erythematosus. Molecular biology reports 37(1): 81–85.
  • Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, & Gunnarsson I, (2015) IL-17 and IL-23 in lupus nephritis-association to histopathology and response to treatment. BMC immunology 16(1): 7.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.